Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease

Overview

The purpose of this study is to determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active Crohn's Disease (CD) or indeterminate colitis (IBDU) that is refractory to conventional, immunosuppressive therapy. In addition, the study will determine the effect of PEG lavage alone on fecal calprotectin and gut microbiota in patients who are undergoing a PEG lavage for clinical care.

Full Title of Study: “An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2020

Detailed Description

Investigators will evaluate the efficacy of a novel treatment regimen, employing non-immunosuppressive medications, in the management of refractory CD or IBDU. Refractory patients include those patients who have experienced loss of responsiveness (LOR) or primary nonresponse to an immunomodulator or a biologic. Investigators will treat participants with a combination of gut microbiota-targeted therapies to restore a healthy gut microbiome composition. Investigators believe that this strategy will both treat the gut inflammation associated with inflammatory bowel disease (IBD) as well as salvage response to immune suppressive therapies. Investigators will also evaluate the effect of PEG lavage alone on fecal calprotectin and gut microbiota. Participants in this arm, will be undergoing a PEG lavage in preparation for a endoscopy for clinical care. They will be asked to provide stool samples, prior to and after their PEG lavage. Participants will not be receiving any investigational treatments.

Interventions

  • Drug: Vancomycin
    • Oral suspension 4 times daily (Day 1-14)
  • Drug: Neomycin
    • Oral three times daily (Days 1-3)
  • Drug: Ciprofloxacin
    • Oral twice daily (Days 4-14)
  • Drug: Polyethylene Glycol 3350
    • Dissolved in Gatorade on day 2
  • Drug: Fluconazole
    • Orally once daily (Day 1-14)

Arms, Groups and Cohorts

  • Experimental: Group 1-Fluconazole
    • Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
  • Placebo Comparator: Group 1-Placebo
    • Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
  • No Intervention: Group 2
    • Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.

Clinical Trial Outcome Measures

Primary Measures

  • Change in FCP in Group 2 Participants
    • Time Frame: change from baseline to day 12
    • Change in fecal calprotectin between stool samples collected at baseline and day 12 after procedure in Group 2 participants.
  • Change in Disease Activity by Pediatric Crohn’s Disease Activity Index
    • Time Frame: Baseline, Day 15
    • The primary endpoint will be the change in disease activity, as measured by Pediatric Crohn’s Disease Activity Index (PCDAI) score, between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The Pediatric Crohn’s Disease Activity Index is a clinical score which takes into account general well being, degree of abdominal pain, number of liquid stools per day, abdominal physical examination, and Crohn’s disease complications.
  • Change in Disease Activity by Fecal Calprotectin (FCP)
    • Time Frame: Baseline, Day 15
    • The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.

Secondary Measures

  • Change in C-reactive Protein (CRP)
    • Time Frame: Baseline, Day 15
    • A secondary outcome measure will be the change in C-reactive protein between the enrollment visit and day 15. The C-reactive protein is a blood test which measures systemic inflammation.
  • Safety and Tolerability of the Treatment Regimen Based on Medication Side Effects and/or Adverse Events
    • Time Frame: 105 days

Participating in This Clinical Trial

Group 1 Inclusion Criteria:

  • Males or females 6-18 years of age – Current weight >10 kg (or 22 lb) – Ability to swallow pills – Normal kidney function – Normal Aspartate transaminase (AST), Alanine transaminase (ALT), and alkaline phosphatase – Active CD or IBDU defined as PCDAI ≥ 30 – C-Reactive Protein (CRP) ≥ 15mg/L (or 1.5mg/dL) or fecal calprotectin (FCP)>350mcg/g (within one month of enrollment) – Have been treated with one of the following therapies for at least 8 weeks with primary nonresponse or an initial response, followed by loss of response [LOR] (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab, or ustekinumab **These medications must have been administered at standard, therapeutic dosages. Exclusion Criteria:

  • Known allergy or intolerance to aminoglycosides or any of the medications used in this study – Current use of one or more of the following medications: 5-fluorouracil, digoxin, anticoagulants, theophylline, phenytoin, probenecid, duloxetine, clozapine, sildenafil, hydrochlorothiazide, cyclosporine, hypoglycemics, terfenadine, tacrolimus, rifabutin, midazolam, and voriconazole – Known diagnosis of diabetes mellitus – Known or suspected structuring disease producing obstructive symptoms – Active Clostridium difficile infection – Prolonged QTc interval as seen on enrollment EKG – Current use of antibiotics – Starting or increasing the dose of an IBD related medication within 4 weeks of screening Group 2 Inclusion Criteria – Males or females 10 years of age and older. – Patients undergoing a clinical GI endoscopy due to suspicion for active intestinal inflammation determined by physician global assessment (PGA). – Undergoing a bowel preparation as part of clinical care. – Parental/guardian permission (informed consent) and if appropriate, child assent. Exclusion Criteria – Antibiotic use within the past 30 days. – Current presence of an ostomy bag. – Patients undergoing a non- polyethylene glycol 3350 cleanout. – Unwillingness to provide informed consent. – Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Hospital of Philadelphia
  • Collaborator
    • University of Pennsylvania
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lindsey Albenberg, DO, Principal Investigator, Children’s Hospital of Philadelphia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.